|1.||Motoo, Yoshiharu: 2 articles (11/2014 - 01/2007)|
|2.||Taga, H: 2 articles (01/2001 - 04/2000)|
|3.||Sawabu, N: 2 articles (01/2001 - 04/2000)|
|4.||Motoo, Y: 2 articles (01/2001 - 04/2000)|
|5.||Su, S B: 2 articles (01/2001 - 04/2000)|
|6.||Xie, M J: 2 articles (01/2001 - 04/2000)|
|7.||Takata, Takanobu: 1 article (11/2014)|
|8.||Tomosugi, Naohisa: 1 article (11/2014)|
|9.||Chen, Chi-Yang: 1 article (06/2010)|
|10.||Kuo, Tzong-Fu: 1 article (06/2010)|
05/01/2001 - "These findings suggest that TJ-10 is effective for controlling the manifestation of pain in ligatured nerves, by local effect, not by general analgesic effect."
05/01/2001 - "To verify the effectiveness of TJ-10, Wistar rats with chronic neuralgia of the mandibular nerve were prepared and TJ-10 was administered to them for 4 weeks following the manifestation of pain in the mandibular region. "
10/01/1999 - "The aim of this study was to analyze the expression of PAP and the effect of TJ-10 in a spontaneous chronic pancreatitis model. "
01/01/2007 - "These results suggest that TJ-10 has a therapeutic effect on chronic pancreatitis by the suppression of acinar cell apoptosis via the Fas/FasL system."
01/01/2001 - "We reported an anti-inflammatory effect of the herbal medicine Saiko-keishi-to (TJ-10) on chronic pancreatitis. "
01/01/2001 - "Antifibrotic effect of the herbal medicine Saiko-keishi-to (TJ-10) on chronic pancreatitis in the WBN/Kob rat."
04/01/2000 - "Effect of herbal medicine Saiko-keishi-to (TJ-10) on rat spontaneous chronic pancreatitis: comparison with other herbal medicines."
11/01/2014 - "Among its various mechanisms elucidated so far, TJ-10 inhibits the production of transforming growth factor-β1 (TGF-β1) and development of pancreatic fibrosis in vivo. "
01/01/2001 - "These results suggest that TJ-10 inhibits the pancreatic fibrosis by the suppression of TGF-beta1 expression."
07/01/2003 - "The effects of two similar herbal medicines (Sho-saiko-to and Saiko-keishi-to: TJ-9 and TJ-10, respectively) were elucidated on the hepatocyte injury, fibrosis and preneoplastic lesions development using a choline-deficient-L-amino acid-defined (CDAA) diet rat liver carcinogenesis model. "
01/01/2008 - "Those found to retard the progression of experimental CP and fibrosis in animal models include interferon (IFN) beta and IFN-gamma; a Japanese herbal medicine called Saiko-keishi-to (TJ-10); curcumin; PPAR-gamma ligand (troglitazone); antioxidants (vitamin A, vitamin E, DA 9601 and epigallocatechin-3-gallate); a protease inhibitor (camostat mesilate) and hydroxymethylglutaryl-CoA inhibitor (lovastatin). "
|5.||Body Weight (Weight, Body)
01/01/2007 - "Four-week-old male WBN/Kob rats were fed a special pellet diet (MB-3) with or without TJ-10 (80 mg/100 g body weight) for 20 weeks. "
01/01/2001 - "Four-week-old male WBN/Kob rats were fed a special pellet diet (MB-3) with or without TJ-10 (80 mg/100 g body weight) for 20 weeks. "
10/01/1999 - "Four-week-old male WBN/Kob rats were fed with a special pellet diet (MB-3), and TJ-10 (80 mg/100 g body weight/day) was orally administered for 16 weeks. "
|1.||Nitric Oxide Synthase (NO Synthase)
|3.||Transforming Growth Factor beta1 (TGF beta 1)
|6.||Protease Inhibitors (Protease Inhibitor)
|7.||Nitric Oxide (Nitrogen Monoxide)
|1.||Kampo Medicine (Kampo)
|2.||Chinese Traditional Medicine (Traditional Chinese Medicine)